Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Onno W Akkerman

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
The Lancet. Infectious Diseases|April 26, 2024
Endobronchial tuberculosisSiawosh K Eskandari, Onno W Akkerman
The Lancet. Infectious Diseases|July 23, 2022
Destroyed left lung due to multidrug-resistant Mycobacterium tuberculosisSiawosh K Eskandari, Onno W Akkerman
Antimicrobial Agents and Chemotherapy|January 4, 2017
Statin Adjunctive Therapy for Tuberculosis TreatmentJan-Willem C Alffenaar, Onno W Akkerman, Rob van Hest
Nederlands Tijdschrift Voor Geneeskunde|April 21, 2016
[An asylum seeker with an abnormal chest X-ray]Onno W Akkerman, Mieneke Rook, Tjip S van der Werf
Pathogens (Basel, Switzerland)|January 8, 2025
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) DrugsAntonia Morita Iswari Saktiawati, Anca Vasiliu, Francesca Saluzzo, et al.
The New England Journal of Medicine|June 11, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisMathieu S Bolhuis, Tjip S van der Werf, Onno W Akkerman
Infection|July 2, 2024
Post-tuberculosis treatment paradoxical reactionsSabine M Hermans, Onno W Akkerman, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|December 3, 2014
Raltegravir and rifampicin in patients with HIV and tuberculosisSandor Klis, Alper Daskapan, Onno W Akkerman, et al.
ERJ Open Research|April 15, 2025
ERS Congress 2024: highlights from the Respiratory Infections AssemblyLeander Jonckheere, Efthymia Papadopoulou, Federica Piedepalumbo, et al.
The European Respiratory Journal|November 9, 2019
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?Jan-Willem C Alffenaar, Onno W Akkerman, Simon Tiberi, et al.
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
The Lancet. Infectious Diseases|April 26, 2024
Endobronchial tuberculosisSiawosh K Eskandari, Onno W Akkerman
The Lancet. Infectious Diseases|July 23, 2022
Destroyed left lung due to multidrug-resistant Mycobacterium tuberculosisSiawosh K Eskandari, Onno W Akkerman
Antimicrobial Agents and Chemotherapy|January 4, 2017
Statin Adjunctive Therapy for Tuberculosis TreatmentJan-Willem C Alffenaar, Onno W Akkerman, Rob van Hest
Nederlands Tijdschrift Voor Geneeskunde|April 21, 2016
[An asylum seeker with an abnormal chest X-ray]Onno W Akkerman, Mieneke Rook, Tjip S van der Werf
Pathogens (Basel, Switzerland)|January 8, 2025
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) DrugsAntonia Morita Iswari Saktiawati, Anca Vasiliu, Francesca Saluzzo, et al.
The New England Journal of Medicine|June 11, 2020
Treatment of Highly Drug-Resistant Pulmonary TuberculosisMathieu S Bolhuis, Tjip S van der Werf, Onno W Akkerman
Infection|July 2, 2024
Post-tuberculosis treatment paradoxical reactionsSabine M Hermans, Onno W Akkerman, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|December 3, 2014
Raltegravir and rifampicin in patients with HIV and tuberculosisSandor Klis, Alper Daskapan, Onno W Akkerman, et al.
ERJ Open Research|April 15, 2025
ERS Congress 2024: highlights from the Respiratory Infections AssemblyLeander Jonckheere, Efthymia Papadopoulou, Federica Piedepalumbo, et al.
The European Respiratory Journal|November 9, 2019
Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?Jan-Willem C Alffenaar, Onno W Akkerman, Simon Tiberi, et al.
Pageof 12